A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Protocol No
MERCK-MK-5684-01A
Staff Member
Kathryn Bylow
Phase
I/II
Summary

This project is being done to test the safety of MK-5684 when given alone and in combination with olaparib, docetaxel, or cabazitaxel.
Objective
Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Prostate, Prostate and Urologic Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06353386